ARCHIVES

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

September issue of Business & Regulatory Report included (8-page issue).

October 4, 2002

Also Stillman named director, Cold Spring Harbor, Watson is chancellor.

December 12, 2003

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

Protocols Approved During The Month of September 2001

October 26, 2001

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003

16 Institutions Win NCI Awards for Phase I Trials

May 2, 2003